Continuously consider new data to improve our impact on patient health
Our ambition is to advance research and contribute to the development of new, innovative and effective cancer therapies. To help better understand and treat cancer, we are progressively considering new structured health data sets within our Health Data Warehouse.
- Améliorer la qualité de vie, l’adhérence au traitement et la survie globale des patients.
- Apporter à chacun un accompagnement plus adapté, humain et personnalisé.
- En france l'accès au marché pour les solutions de télésurveillance en cancérologie est rendue possible par l'entrée dans le droit commun de la télésurveillance.
- Pour obtenir ce remboursement nous devons démontrer auprès de la HAS que nous maintenons des bénéfices cliniques et organisationnelles par des études cliniques et par la donnée de vie réelle.
- Faire avancer la science et pousser de nouveaux standards basés sur des questionnaires ePROs (Patient-Reported-Outcome)
- Comprendre précisément chaque patient grâce aux données cliniques, biologiques et comportementales
Proving our impact and contributing to medical research
We want to evaluate our solution through clinical trials, and scientifically demonstrate its benefits on patient quality of life and treatment adherence. We work with cancer research institutes, healthcare institutions and scientists for this purpose.
Optimizing of surgical care pathway for kidney tumors by digitizing peri-operative nursing coordination
To evaluate the effectiveness of digitizing perioperative nursing coordination on the use of unscheduled care (RSNP) during the month following nephrectomy for kidney tumor.
Bordeaux University Hospital
Caen University Hospital
CHU Rennes
Strasbourg University Hospital
Toulouse University Hospital
APHP Henri Mondor
CHU Angers
APHM Conception Hospital
Medipole Cabestany
CH Mont de Marsan
CHU Nîmes
Prof. Jean-Christophe BERNHARD
Department of Urological Surgery and Renal Transplantation
CHU BORDEAUX
Odyssea personalized approach: randomized Phase II study to determine the effectiveness of a personalized approach in improving quality of life in patients receiving adjuvant hormone therapy for early-stage breast cancer.
The main objective of OPERA is to determine the effectiveness of a personalized approach, consisting of a multi-component, multi-level interventional application (first module), compared with standard care, in improving quality of life (QOL) after 12 weeks.
Gustave Roussy Institute
Léon Bérard Centre
Center Georges François Leclerc
Center François Baclesse
Dr. Inês VAZ-LUIS
Breast cancer treatment service
Gustave Roussy
Assessing the clinical and organizational impact of remote patient monitoring during cancer treatment
To study the impact of the Resilience RPM system on clinical outcomes, healthcare resource utilization, costs and the experience of patients diagnosed with cancer and receiving active treatment.
> 15 centers
Dr. Inês VAZ-LUIS
Breast cancer treatment service
Gustave Roussy
Évaluation de l'impact clinique et organisationnel de la surveillance à distance des patients pendant le traitement du cancer
L’objectif principal de l’étude sera d’évaluer l’impact du dispositif de télésurveillance Resilience PRO sur la morbidité en lien avec le cancer.
100+ centres
Ines VAZ-LUIS; Gustave Roussy, Service de traitement du cancer du sein; Breast Cancer Survivorship Research Group; Unit INSERM 981
STEpwise research program to promote INGeniouS online support solutions for the relief of cancer-related fatigue
The main objective of SteppingSTONE is to compare the effectiveness of three different modalities of digital assistance (educational material; educational material plus self-management program - self-administered; educational material plus self-management program - therapist-guided) in reducing the perceived burden of CRF.
Gustave Roussy
Bordeaux University Hospital
Institut Bergonié
Dr Ines VAZ-LUIS
Gustave Roussy
Groupe de Recherche sur la Survie du Cancer du Sein (Breast Cancer Survival Research Group)
INSERM Unit 981
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
The aim of this study (Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics; CAPRI) was to evaluate an intervention combining nurse navigator monitoring and a mobile app for patients receiving oral anticancer agents in addition to usual care, designed to simultaneously pursue three dimensions: improving the patient experience of care; improving the health of the target population; and reducing the per capita cost of healthcare.
Olivier Mir, Marie Ferrua, Aude Fourcade, Delphine Mathivon, Adeline Duflot-Boukobza, Sarah Dumont, Eric Baudin, Suzette Delaloge, David Malka, Laurence Albiges, Patricia Pautier, Caroline Robert, David Planchard, Stéphane de Botton, Florian Scotté, François Lemare, May Abbas, Marilène Guillet, Vanessa Puglisi, Mario Di Palma & Etienne Minvielle
Implementing a PROACTive care pathway to Empower and Support Survivors of Breast Cancer
Optimal and comprehensive survivorship care, beyond screening for recurrence and new cancers, and including health promotion, management of physical and psychosocial needs and chronic disease, is insufficiently delivered. To increase patient empowerment and maximize the uptake of multidisciplinary supportive care strategies to serve all survivorship needs, we implemented a proactive survivorship care pathway for patients with early breast cancer at the end of primary treatment phase (surgery, chemotherapy, radiotherapy).
Maria Alice Franzoi, Lena Degousée, Elise Martin, Patricia Miguel Semedo, Marion Aupomerol, Davide Soldato, Antonio Di Meglio, Camila Chiodi, Aude Barbier, Hajer Chaouachi, Nathalie Renvoisé, Diane Boinon, Léonor Fasse, Joana Ribeiro, Jean Bernard Le-Provost, Johanna Arvis, Céline Lazorthes, Mario di Palma, Anne de Jesus, Bruno Raynard, Arnaud Pagès, Suzette Delaloge, Barbara Pistilli, Florian Scotté, and Ines Vaz-Luis
Digital transformation of perioperative protocols coordinated by the renal surgery nurse for improved recovery and ambulatory surgery using the UroConnect® application.
Robotic-assisted partial nephrectomy (RAPN) is a standard of care for localized renal tumors. It provides good carcinological control while limiting complications. Despite its many advantages, the economic viability of robotic assistance remains a challenge in the French healthcare system. With the aim of improving the efficiency of nursing care within these protocols, we have set up digitalized nurse coordination by developing a urological perioperative application: UroConnect®. This device is offered to patients by nurse coordinators during a preoperative visit.
G.Margue, E.Callede, S.Ricard, F.Picard, C.Dubernet, G.Robert, F.Bladou, J.C.Bernhard.
The Resilience Health Data Warehouse
Resilience was authorized to set up its Health Data Warehouse by CNIL deliberation no. 2022-049 on April 21, 2022. Intended to be used for research, studies or evaluations in the healthcare field, this database enables us to face three major challenges:
Grâce aux données anonymisées récoltées auprès de nos établissements partenaires, nous améliorons continuellement notre solution. Afin de répondre aux besoins des soignants, nous sommes ainsi en mesure de développer régulièrement de nouvelles fonctionnalités sur la prédictions des effets secondaires ou des rechutes.
Les données recueillies en vie réelle auprès de nos utilisateurs nous permettront d'évaluer et étudier les impacts de notre solution de télésurveillance sur l'organisation des soins et son adoption par les patients et les soignants.
- Proposer un parcours unique et adresser le bon soin, au bon moment.
- Comprendre précisément chaque patient grâce aux données cliniques, biologiques et comportementales collectées.
Elodie, Fanny, Arlindo, Maximilien, Carlota: they are oncologists, psychiatrists, pharmacists or researchers. They work every day to study and understand the impact of Resilience on patients and healthcare professionals.
Are you a healthcare professional interested in finding out more about Resilience? We'd love to hear from you!